Sanofi has entered into a global research collaboration and licensing option with Rib-X Pharmaceuticals to develop and commercialise novel classes of antibiotics resulting from Rib-X’s RX-04 programme for the treatment of drug-resistant pathogens. Sanofi will have the rights to develop multiple products from the collaboration, which will initially focus on at least four target product profiles.